Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Public ClinicalTrials.gov record NCT00985517. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.
Study identification
- NCT ID
- NCT00985517
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 57 participants
Conditions and interventions
Conditions
Interventions
- CERE-120: Adeno-Associated Virus Delivery of Neurturin Biological
- Sham Surgery Procedure
Biological · Procedure
Eligibility (public fields only)
- Age range
- 35 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 29, 2009 (Actual)
- Primary completion
- Nov 9, 2014 (Actual)
- Completion
- Nov 16, 2017 (Actual)
- Last update posted
- Apr 16, 2020
2009 – 2017
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | — | — |
| Stanford School of Medicine | Palo Alto | California | — | — |
| University of California, San Francisco | San Francisco | California | — | — |
| Emory University | Atlanta | Georgia | — | — |
| Rush University Medical Center | Chicago | Illinois | — | — |
| Beth Israel Medical Center | New York | New York | — | — |
| Columbia University Medical Center | New York | New York | — | — |
| Mount Sinai Medical Center | New York | New York | — | — |
| Duke University | Durham | North Carolina | — | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | — | — |
| Baylor College of Medicine | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00985517, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2020 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00985517 live on ClinicalTrials.gov.